Compare Johnson Controls International PLC (JCI) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson Controls International PLC vs Sanofi SA — how do they compare? Johnson Controls International PLC trades at $157.38 (market cap $93.28B), while Sanofi SA trades at $40.04 (market cap $95.18B). The key difference: Johnson Controls International PLC and Sanofi SA are close in size by market cap, and Sanofi SA pays the higher dividend (6.01%). Which is the better fit depends on your goals — on Pluang, investors hold Johnson Controls International PLC for 65 Days and Sanofi SA for 94 Days on average.
| JCI | SNY | |
|---|---|---|
Market Cap | $93.28B | $95.18B |
Volume | 2,786,476 | 2,995,646 |
Sector | Basic Materials | Health |
52-Week High | $158.76 | $52.34 |
52-Week Low | $105.55 | $39.51 |
Typical Hold Time | 65 Days | 94 Days |
Enterprise Value | $102.12B | $114.48B |
Dividend Yield | 1.04% | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson Controls International (JCI) trades at $157.44, up 0.97% on the day, reflecting strong momentum after beating earnings estimates for three consecutive quarters. The stock exhibits a bullish technical outlook, trading above key support levels, while fundamentals are supported by a 13.94% net income margin and robust ROE of 24.42%. Recent news highlights inclusion in AI industrial stock recommendations and strong Q3 2026 results with raised full-year guidance.
The outlook for JCI remains positive, driven by earnings outperformance and strong demand in thermal management and building systems. Key opportunities include expanding margins and strategic positioning in energy efficiency markets. Risks involve elevated valuation multiples and increasing debt-to-asset ratios, which could pressure the stock if growth moderates.
Sanofi (SNY) trades at $40.07, down 0.32% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.21 exceeding the $1.10 estimate. Revenue for 2025 reached $46.72 billion, with a net income margin of 16.72%. Recent news highlights a significant $8 billion immunology alliance expansion with Regeneron, signaling strategic growth initiatives.
The outlook is mixed; solid profitability and a strategic partnership provide upside potential, but a projected net income decline to $4.0 billion in 2026 and bearish technical indicators pose risks. Analyst sentiment is cautiously optimistic with a 44% buy rating, though investors should monitor execution of new collaborations and patent expiration impacts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson Controls International PLC
Johnson Controls manufactures, installs, and services HVAC systems, building management systems and controls, industrial refrigeration systems, and fire and security solutions. Commercial HVAC accounts for about 40% of sales, fire and security also represents 40% of sales, and residential HVAC, industrial refrigeration, and other solutions account for the remaining 20% of revenue. In fiscal 2021, Johnson Controls generated over $23.5 billion in revenue.
Read more on JCI →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
